ATE449192T1 - Mit dem risiko von obesität und typ-2-diabetes assoziierter haplotyp des gens enpp1 (pc1) und anwendungen davon - Google Patents
Mit dem risiko von obesität und typ-2-diabetes assoziierter haplotyp des gens enpp1 (pc1) und anwendungen davonInfo
- Publication number
- ATE449192T1 ATE449192T1 AT06763749T AT06763749T ATE449192T1 AT E449192 T1 ATE449192 T1 AT E449192T1 AT 06763749 T AT06763749 T AT 06763749T AT 06763749 T AT06763749 T AT 06763749T AT E449192 T1 ATE449192 T1 AT E449192T1
- Authority
- AT
- Austria
- Prior art keywords
- obesity
- haplotype
- risk
- determining
- enpp1
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 7
- 235000020824 obesity Nutrition 0.000 title abstract 7
- 102000054766 genetic haplotypes Human genes 0.000 title abstract 3
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 title abstract 2
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
- 230000007170 pathology Effects 0.000 abstract 3
- 239000013614 RNA sample Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05291298A EP1736553A1 (de) | 2005-06-17 | 2005-06-17 | ENPP1 (PC-1) Haplotyp Gen zur Risikobestimmung von Fettsucht und Typ 2 Diabetes und seine Anwendungen |
| PCT/EP2006/063256 WO2006134154A2 (en) | 2005-06-17 | 2006-06-15 | Enpp1 (pc-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE449192T1 true ATE449192T1 (de) | 2009-12-15 |
Family
ID=35266874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06763749T ATE449192T1 (de) | 2005-06-17 | 2006-06-15 | Mit dem risiko von obesität und typ-2-diabetes assoziierter haplotyp des gens enpp1 (pc1) und anwendungen davon |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8017324B1 (de) |
| EP (2) | EP1736553A1 (de) |
| JP (1) | JP5297799B2 (de) |
| AT (1) | ATE449192T1 (de) |
| CA (1) | CA2612160A1 (de) |
| DE (1) | DE602006010544D1 (de) |
| ES (1) | ES2337181T3 (de) |
| WO (1) | WO2006134154A2 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2104743A1 (de) * | 2007-01-19 | 2009-09-30 | Integragen | Suszeptibilitätsgen iglc für menschliche diabetes |
| EP2102368A1 (de) * | 2007-01-19 | 2009-09-23 | Integragen | Suszeptibilitätsgen btbd9 für menschliche diabetes |
| US20100151462A1 (en) | 2007-02-21 | 2010-06-17 | Integragen | Human diabetes susceptibility shank2 gene |
| US20100203517A1 (en) * | 2007-02-21 | 2010-08-12 | Integragen | Human diabetes susceptibility pebp4 gene |
| EP1978107A1 (de) * | 2007-04-03 | 2008-10-08 | Centre National De La Recherche Scientifique (Cnrs) | FTO-Gen-Polymorphismen in Verbindung mit Fettleibigkeit und/oder Diabetes Typ II |
| CA2684661A1 (en) * | 2007-05-04 | 2008-11-13 | Integragen | Human diabetes susceptibility eefsec gene |
| JP5427352B2 (ja) * | 2007-11-16 | 2014-02-26 | 国立大学法人 東京大学 | ヒト体脂肪量と関連する遺伝子多型に基づく肥満発症リスクの判定方法 |
| US8877443B2 (en) | 2009-05-15 | 2014-11-04 | The University Of Tokyo | Method and kit for evaluation of predisposition to development of obesity, anti-obesity agent and method for screening thereof, non-human animal, adipose tissue, adipocyte, method for production of transgenic mouse, antigen, and antibody |
| KR101486877B1 (ko) * | 2014-06-25 | 2015-02-05 | 대한민국 | 공복 혈청 혈당과 연관된 단일염기다형성 정보를 제공하는 방법 |
| AU2018218280A1 (en) * | 2017-02-07 | 2019-08-29 | The Regents Of The University Of California | Gene therapy for haploinsufficiency |
| AU2020207967A1 (en) * | 2019-01-18 | 2021-07-29 | Inozyme Pharma, Inc. | Treatment of diseases involving deficiency of ENPP1 or ENPP3 |
| CN110244058B (zh) * | 2019-06-10 | 2020-05-22 | 浙江大学 | Enpp1在制备高级别浆液性卵巢癌诊断及预后试剂盒中的应用 |
| EP4225927A1 (de) * | 2020-10-08 | 2023-08-16 | Inozyme Pharma, Inc. | Leberspezifische herstellung von enpp1 oder enpp3 |
| CN114093518B (zh) * | 2022-01-24 | 2022-04-26 | 北京健康有益科技有限公司 | 一种基于肥胖度的糖尿病风险评估系统及评估方法 |
| WO2023191898A1 (en) * | 2022-03-30 | 2023-10-05 | Yale University | Method and compositions for treatment, amelioration, and/or prevention of diffuse idiopathic skeletal hyperostosis (dish) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1741300A (en) * | 1998-11-18 | 2000-06-05 | Ospedale Casa Sollievo Della Sofferenza | Polymorphic human pc-1 sequences associated with insulin resistance |
-
2005
- 2005-06-17 EP EP05291298A patent/EP1736553A1/de not_active Withdrawn
-
2006
- 2006-06-15 WO PCT/EP2006/063256 patent/WO2006134154A2/en active Application Filing
- 2006-06-15 US US11/917,586 patent/US8017324B1/en not_active Expired - Fee Related
- 2006-06-15 EP EP06763749A patent/EP1891237B9/de not_active Not-in-force
- 2006-06-15 ES ES06763749T patent/ES2337181T3/es active Active
- 2006-06-15 AT AT06763749T patent/ATE449192T1/de not_active IP Right Cessation
- 2006-06-15 DE DE602006010544T patent/DE602006010544D1/de active Active
- 2006-06-15 CA CA002612160A patent/CA2612160A1/en active Pending
- 2006-06-15 JP JP2008516328A patent/JP5297799B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-03 US US13/197,327 patent/US20120009592A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8017324B1 (en) | 2011-09-13 |
| JP5297799B2 (ja) | 2013-09-25 |
| EP1891237B9 (de) | 2010-07-21 |
| EP1891237A2 (de) | 2008-02-27 |
| ES2337181T3 (es) | 2010-04-21 |
| CA2612160A1 (en) | 2006-12-21 |
| WO2006134154A3 (en) | 2007-02-01 |
| JP2008546380A (ja) | 2008-12-25 |
| WO2006134154A2 (en) | 2006-12-21 |
| US20120009592A1 (en) | 2012-01-12 |
| EP1736553A1 (de) | 2006-12-27 |
| DE602006010544D1 (de) | 2009-12-31 |
| EP1891237B1 (de) | 2009-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE449192T1 (de) | Mit dem risiko von obesität und typ-2-diabetes assoziierter haplotyp des gens enpp1 (pc1) und anwendungen davon | |
| SG134283A1 (en) | Biomarkers for liver fibrotic injury | |
| WO2005087953A8 (en) | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | |
| BRPI0506771A (pt) | anticorpo, e, composição farmacêutica | |
| Chien et al. | Organomercurials removal by heterogeneous merB genes harboring bacterial strains | |
| MXPA05014215A (es) | Mapeo de genoma de elementos funcionales de adn y proteinas celulares. | |
| BRPI0509023A (pt) | nitrila hidratase de rhodococcus | |
| WO2006096737A3 (en) | Diagnostic and therapeutic target for macular degeneration | |
| DK1507002T3 (da) | Termostabilt Taq-polymerasefragment | |
| ATE465173T1 (de) | Verändertes vp-1capsidprotein von parvovirus b19 | |
| WO2010011283A3 (en) | Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases | |
| WO2003093316A3 (en) | Immunoglobulin-domain containing cell surface recognition molecules | |
| Jennings et al. | RNA unwinding activity of the hepatitis C virus NS3 helicase is modulated by the NS5B polymerase | |
| WO2008051511A3 (en) | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| WO2005070042A8 (en) | Novel chemical compounds | |
| WO2006099365A3 (en) | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | |
| WO2008065544A3 (en) | Genetic predictors of risk for type 2 diabetes mellitus | |
| DE602005016290D1 (de) | Glichkeit | |
| WO2004070012A3 (en) | Cell-killing molecules and methods of use thereof | |
| DE60025011D1 (de) | Dna polymerase lambda und ihre verwendungen | |
| WO2007068913A3 (en) | SRCR-B Domain Containing Proteins | |
| WO2005091751A3 (en) | Novel gene associated with type 1 diabetes and methods of use | |
| WO2005005471A3 (en) | Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome | |
| ATE465248T1 (de) | Humane cyclooxygenase-3 und ihre verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |